Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 18.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, April 27, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
A major issue in the treatment of cancer is the development of resistance to therapies. The acquisition of therapy resistance is often referred to as an evolutionary process, wherein strong selection pressures imposed by therapies select for emergence of resistant clones via an ecological principle known as “competitive release.” Despite a survey by the American Association of Medical Colleges and the Howard Hughes Medical Institute calling for the incorporation of evolutionary theory as a core competency in medical education1, the coverage is still not commensurate with its importance.2 This can result in a competency gap of clinicians and physician scientists treating cancer patients. This conference will meet the need for practical application of evolutionary theory by providing a venue to synthesize concepts in evolutionary dynamics from basic cancer research into clinical applications.
Two of the most critical issues in current cancer research are 1) defining the biological basis for the vast intratumoral heterogeneity observed in patients and 2) understanding the underlying processes of developing therapy resistance. Both issues are rooted in Darwinian evolutionary dynamics as tumors are complex, active ecosystems. The conference will be divided into two broad themes to address these challenges: 1) Evolutionary Dynamics in Carcinogenesis (including prevention and early detection strategies – identifying indolent from aggressive pre-cancers); 2) Evolutionary Dynamics in Therapy Response and Emergence of Resistance. Within each of the themes, the conference will explore a) the importance of (epi)genetic heterogeneity and its generation, b) the role of tissue microenvironments in the genesis, progression and responses to therapy for cancers, c) methods to monitor and model cancer risk, development and therapeutic responses, and d) interventions to control cancer evolution, whether for prevention or therapy.
After participating in this CME activity, physicians should be able to:
1. Explain the complexities and strategies of Darwinian evolution in cancer.
2. Articulate the relevance of evolutionary dynamics in carcinogenesis and therapy response.
3. Evaluate strategies to quantify tumor heterogeneity at baseline and strategies to longitudinally monitor evolutionary dynamics during therapy response.
4. Identify areas in which evolutionary understanding of cancer could be applied to develop improved interventions for prevention, early detection, and therapy.
5. Translate evolutionary dynamic principles into their own research.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants and will be disclosed at the activity.
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or email@example.com.